NAC for Trichotillomania: Adult vs Pediatric Evidence

NAC has positive randomized evidence for trichotillomania in adults—but that result did not replicate in children and adolescents. This adult-versus-pediatric split is the most important fact to understand before turning NAC into a generic “hair-pulling supplement.”

Trichotillomania is a body-focused repetitive behavior characterized by recurrent hair pulling that causes hair loss and clinically significant distress or impairment. NAC has been studied because it can influence glutamatergic signaling in brain circuits involved in compulsive and habitual behavior.

NAC for trichotillomania at a glance

Population	Study	Result
Adults	50-person randomized double-blind placebo-controlled trial	Positive. NAC improved hair-pulling symptoms.
Children/adolescents	39-person randomized double-blind placebo-controlled trial	Negative. No significant benefit over placebo.

The adult randomized trial

The key adult study randomized 50 adults with trichotillomania to NAC or placebo for 12 weeks.

The adult trial used oral NAC in the range of 1,200-2,400 mg/day.

Participants receiving NAC had significantly greater reductions in hair-pulling symptoms across validated scales than those receiving placebo.

How large was the adult response?

The study reported a substantially greater proportion of NAC-treated adults as much or very much improved compared with placebo.

This is a legitimate positive randomized result. At the same time, the trial was small and single-center, so it should not be treated as the final word on efficacy, optimal dose or long-term relapse prevention.

The pediatric trial was negative

A later randomized trial in 39 children and adolescents aged 8-17 did not reproduce the adult benefit.

After 12 weeks, there was no significant advantage for NAC over placebo on primary or secondary outcomes. About 25% of NAC-treated participants and 21% of placebo participants were rated responders.

That direct age-specific evidence matters more than assuming a supplement that helped adults should work the same way in children.

Why might adult and pediatric results differ?

The studies were small, so chance is one possibility. Developmental neurobiology, symptom pattern, comorbidity, adherence and placebo response may also differ between children and adults.

Current evidence does not allow a confident explanation. The appropriate conclusion is simply that adult efficacy has not been demonstrated in pediatric trichotillomania.

How might NAC affect hair-pulling behavior?

NAC can influence glutamatergic signaling through the cystine-glutamate antiporter. Glutamate is involved in corticostriatal circuits relevant to compulsive behavior and habit formation.

That mechanism is plausible and fits several studies of body-focused repetitive behaviors, including skin-picking disorder.

Mechanism still does not override the age-specific clinical data: positive in the small adult trial, negative in the pediatric trial.

What dose was studied?

The adult study used 1,200-2,400 mg/day. That is a research range, not a universal personal recommendation.

Higher oral doses can increase gastrointestinal side effects, and medication context matters. See NAC dosage and NAC drug interactions.

How long does NAC take to work?

The adult trial lasted 12 weeks. That tells us that the intervention was evaluated over months rather than as an immediate treatment.

The study does not establish one precise onset time for every responder, and it is not evidence that escalating the dose faster produces a quicker response.

Can NAC replace behavioral therapy?

No.

Habit reversal training and other behavioral approaches are central treatments for trichotillomania. NAC is best understood as an off-label adjunctive option with limited but interesting adult evidence.

Is NAC approved for trichotillomania?

No. NAC is not an approved treatment for trichotillomania. Its use in this setting is based on clinical research and off-label discussion.

Bottom line

NAC has a clear adult signal and a clear pediatric non-replication. The adult 12-week randomized trial is promising enough to take seriously; the negative pediatric trial is equally important. Any responsible NAC article should present both rather than advertising the adult result as if it applies to everyone with hair-pulling disorder.